The US District Court has approved an injunction motion by the FTC, halting Edwards Lifesciences’ acquisition of JenaValve, impacting its full-year 2026 earnings guidance. Edwards will focus on developing its SOJOURN transcatheter AR valve and JOURNEY trial, inherited from JC Medical. JenaValve’s Trilogy Heart Valve awaits FDA approval, as no TAVR devices with an AR indication are on the US market. The FTC sued Edwards to prevent the acquisition, citing concerns about competition. Edwards’ share price fell, impacting the growing TAVR market projected to reach $12.8bn by 2034.

Read more at Yahoo Finance: Edwards’ JenaValve acquisition nixed as FTC injunction approved by court